Marcio Souza, Praxis Precision Medicines CEO
September 3, 2024 11:23 AM EDTUpdated 04:23 PM
R&D

Prax­is' epilep­sy drug re­duces seizures by 46% in pe­di­atric pa­tients in Phase 2 study

Katherine Lewin

News Reporter

Prax­is Pre­ci­sion Med­i­cines re­leased an­oth­er batch of topline da­ta from its epilep­sy pro­gram on Tues­day, this time from the Phase 2 EM­BOLD study in­ves­ti­gat­ing re­lut­rig­ine …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

FDA ap­proves Io­n­is’ treat­ment for a rare meta­bol­ic dis­or­der

A service from the Financial Times